0      0


Cell and Gene Therapy CMC and Manufacturing


Jun 24, 2020 12:00am ‐ Sep 11, 2020 6:08am


Credits: None available.

Description

Cell and Gene Therapy CMC and Manufacturing

Cell and Gene Therapy CMC and Manufacturing: Ensuring the Analysis, Production and Quality Robust and cost-effective characterization and manufacturing presents a core challenge in the commercialization of gene and cell therapies with pressure mounting on CMC, analytical and manufacturing teams to keep up with accelerated development times and cost pressures. Gene and Cell Therapy CMC and Manufacturing examines the critical challenges facing the production, characterization and quality control of gene and cell therapies, with dedicated presentations on rapid CMC development, product and process characterization, upstream and downstream bioprocessing and considerations for personalized and large-scale manufacturing.

  • Transformation from R&D to Manufacturing
    James Warren, PhD, Vice President Pharmaceutical Development
    Ultragenyx
  • Re-thinking Comparability Assessments for Individualized Therapeutics?
    Kathy Francissen, PhD, Senior Director, Pharma Technical Regulatory
    Genentech, A Member of the Roche Group
  • Virtual Inspections: Navigating the New Paradigm
    Monica M. Commerford, PhD, Manager of Regulatory Affairs
    Brammer Bio

Moderator(s):

Speaker(s):

Credits

Credits: None available.

You must be logged in and own this session in order to post comments.